10-Q · May 13, 2026
ClearPoint Neuro reported a strong Q1 2026 with revenue of $12.1 million, which was above estimates of $12.03 million, marking a 43% increase year-over-year. However, the company experienced a diluted EPS loss of $0.32,…
Earnings analysis · 10-Q
CLPT earnings analysis
Filed August 3, 2026 · Our reading of the company's report
The latest report
ClearPoint Neuro delivered $10.880 million of Q2 revenue, up 18% year over year but down roughly 10% from Q1 2026, with growth concentrated in neurosurgery navigation and therapy. Gross margin improved 2 points to 62%,…
Read full summary
ClearPoint Neuro delivered $10.880 million of Q2 revenue, up 18% year over year but down roughly 10% from Q1 2026, with growth concentrated in neurosurgery navigation and therapy. Gross margin improved 2 points to 62%, but IRRAS-related commercial expansion and other operating costs drove the net loss to $11.337 million and EPS to negative $0.38. Liquidity was $29.4 million of cash, while first-half operating cash burn rose to $14.982 million; management expects burn to improve after IRRAS integration.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.38
What stood out
-
Revenue grew 18% year over year
Q2 revenue increased 18% year over year to $10.880 million from $9.215 million. First-half revenue increased 30% to $23.008 million from $17.700 million.
-
Procedure-oriented franchises accelerated
Neurosurgery navigation and therapy revenue rose 62% to $5.552 million, driven by IRRAflow sales and ClearPoint Navigation Software 3.0, while capital equipment and software rose 24% to $1.297 million.
-
Gross margin expanded 2 points
Gross margin improved to 62% from 60% a year earlier, producing gross profit of $6.710 million versus $5.556 million; management attributed the expansion primarily to lower excess and obsolete inventory.
-
Cash supports stated 12-month runway
Liquidity included $29.4 million of cash and cash equivalents at June 30, 2026. The company also had received approximately $48.1 million of net proceeds from two notes under a facility allowing up to $105.0 million in aggregate principal.
What to watch
-
Losses and operating margin deteriorated sharply
The Q2 net loss nearly doubled to $11.337 million from $5.837 million, and diluted EPS declined to negative $0.38 from negative $0.21. Operating loss was approximately $10.244 million, equal to a negative 94.2% operating margin on $10.880 million of revenue.
-
Sequential slowdown and biologics volatility
Revenue declined approximately 10% sequentially from $12 million in Q1 2026 to $10.880 million in Q2, while gross margin fell from 64.0% to 62.0%. Biologics and drug delivery revenue fell 15% year over year to $4.031 million because a prior-year customer product order did not recur.
-
Post-acquisition cost growth outpaced revenue
Operating costs grew materially faster than sales: sales and marketing rose 68% to $6.768 million, general and administrative expense rose 64% to $5.554 million, and R&D rose 21% to $4.632 million, versus 18% revenue growth.
-
Operating cash burn increased
Six-month operating cash use increased to $14.982 million from $8.724 million. Adding $0.859 million of equipment acquisitions implies approximately $15.841 million of six-month cash use before financing, despite management expecting operating cash use to decrease in the remainder of 2026.
-
New CAL facility execution risk
The sole material risk-factor update concerns execution of the preclinical CRO facility, CAL. The company has $29.4 million of cash at June 30, 2026, but warns that CAL requires upfront fixed costs and may not generate enough demand or revenue to justify the investment.
Management's outlook
The 10-Q contains no quantitative revenue or EPS outlook. Management expects revenue to grow over coming years from the IRRAS acquisition and expects operating cash use to decrease during the remainder of 2026 as IRRAS integration is completed; it also states that $29.4 million of cash and cash equivalents is sufficient for at least the next 12 months.
Earlier filings 4
10-K · March 17, 2026
ClearPoint reported record 2025 revenue of $36.97 million (up 18% vs. 2024) driven by product revenue of $23.86 million (+28%) and a 44% increase in neurosurgery navigation & therapy revenue to $14.83 million. The…
10-Q · May 13, 2025
ClearPoint reported Q1 2025 revenue of $8,485,000, up $846,000 or 11.1% year-over-year, driven by product revenue growth. Gross profit rose to $5,132,000 (60.5% margin) but operating loss widened to $6,163,000 (−72.6%…
10-K · February 26, 2025
ClearPoint reported 2024 revenue of $31.39 million, up 31% year-over-year, driven by a 76% increase in product revenue to $18.626 million and growth in disposables for biologics and neurosurgery. The company improved…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.